Faculty Summaries
Elizabeth Hopper-Borge, PhD
Elizabeth Hopper-Borge, PhD
Assistant Professor
Elizabeth.Hopper@fccc.edu
Office Phone: 215-214-1505
Lab Phone: 215-214-3757
Fax: 215-728-3616
Office: W463
  • Lab Overview
    1. Determine the In Vivo role of Abcc10/ABCC10 in resistance

      Joely Jacobs
      ATP-Binding Cassette (ABC) family of transporters extrude a variety of substrates from cells including anticancer agents, bile acids, sterols and moieties bound to glutathione or glucuronidate. Our laboratory is particularly interested in ascertaining MRP7's (ABCC10's) physiology as well as its role in cancer resistance. Recently, using HEK 293- ABCC10 cell lines we have demonstrated that MRP7 confers resistance to taxanes and nucleoside analogs that are used in the treatment of various cancers. Our laboratory has created several mouse models and is using these models in conjunction with pharmacokinetic techniques to elucidate Mrp7's contribution to in vivo resistance.
    2. Biochemistry of ABCC10

      Joely Jacobs & Ekaterina Malofeeva
      We are examining the underlying biochemical requirements for MRP7 (ABCC10) activity. Interestingly ABCC10 has the ability to confer resistance to nucleoside analogs and natural products, this is a unique characteristic of this ABCC family member. Further, ABCC10 has some substrate overlap with another well known, very well characterized ABC transporter, P-glycoprotein. We will use biochemical techniques to further defineABCC10’s activity, as well as to identify sites that ABCC10 requires to actively transport its substrates. We can also use these techniques to characterize and find inhibitors of ABCC10 activity.
    3. Physiological Role of ABCC10

      Joely Jacobs
      Our laboratory is actively investigating the role of ABCC10 in cancer and normal tissues by identifying physiological substrates of this protein and determining tissue polarity. Toward this end we have developed several mouse models for use in these investigations. We are supplementing the in vivo models with the use of other in vitro model systems.
    4. Development of an ABCC10 specific inhibitor

      Elizabeth Hopper-Borge, Michael Levin
      In recently published work we demonstrated that ABCC10 knockdown results in solid tumor in mice and also promotes a less aggressive cancer phenotype. In a collaboration we are developing a specific ABCC10 inhibitor. Recent unpublished workf from our laboratory indicates that simultaneous inhibition of ABCC10 and another well known taxane pump causes lethality in mice receiving taxane treatment. Many of the currently available ABCC10 inhibitors are non specific and inhibit other ABC transporters, hence the need to develop a novel ABCC10 inhibitor.